Abstract
Results of treatment for advanced breast cancer have plateaued indicating the need for new treatment approaches. One such approach, combined endocrine therapy and cytotoxic chemotherapy, has had limited success in current clinical trials. This lack of synergism could be due to the effect of endocrine therapy on tumor cell kinetics, which could inhibit the activity of the cytotoxic drug. Proper sequencing of the two treatment modalities may increase the therapeutic ratio.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
